The US Food and Drug Administration (FDA) has approved journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like vicodin and oxycontin.

The new pill, developed by vertex pharmaceuticals, is intended for short-term pain reliaf following surgery or injury, the associateed press.

While it provides a long-awaited alternative to opioids and over-the-counter painkillers like Ibuprofen, Research Suggests Its Effects IS Effects is Modest Compared to Standard Opioid Treatment.

Unlike opioids, which bind to brain receptors to reduce pain but often lead to dependence and addiction, Journavx Works Differently.

The Medication Blocks Specific Proteins that Trigger Pain Signals Before They Reach The Brain.

“In trying to develop medicines that do’t havhe addictive risks of opioid medicines, a key factor is work to block pain painting before it gots to the brain,” Dr. David altshular, vertex’s executive Vice President and Chief Scientific Officer, Previous Told the Associate Press.

Studies of more than 870 patients who Took Journavx after Foot and Abdominal Surgery Showed that the Drug Provided more relieve than a placebo but was not more effective than a immunoid-cammonophenophenop

“It’s not a slam dunk on effectiveness,” Michael schuh of the mayo clinic, a pharmacist who was not involved in the research, Told the Associated Press. “But it is a slam dunk in that it’s a very different pathway and mechanism of action. So, I think that shows a lot promise.”

One Major Concern is cost. Journavx will have a list price of $ 15.50 per pill, compared to generic opioids, which cost $ 1 or less.

Some reported side effects inclined nausea, constipation, itching, rash and headache, but no risk of addiction.

“The new medication has side effects that are inharetly, not only different, but don’t the risk of Substance Abuse and Other Key Side Effects Associateed With Opioids,” Charles Argofff of the Albany Medical Center in New York, Who Consulted for Vertex on the Drug’s Development, Told the Associated Press.

The Approval Marks the First Major Advancement in Pain treatment in more than two decades.

Vertex began development the drug in the early 2000s, as opioid overdoses surgged due to mass prescription for chronic conditions like arthritis and back pain.

While Opioid prescriptions have sharply declined in recent years, the current epidemic is mostly fuled by Ilicit Fentanyl, Rather Than Pharmaceutical Opioids, The Associated Prearted Presorted Reported.

Vertex has attracted Much Interest, but the Drugmaker’s Stock Took a Hit in December after disappointing results in a study of chronic nereve pain.

Despite this, the company plans to continue with another late-stage trial in hopes of getting fda approval for Chronic Pain Treatment.

© 2025 HealthdayAll rights reserved.